Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 16, 2026Oncology and TherapyOpen Access

A Comprehensive Review of the Role of Zanubrutinib for Patients with Chronic Lymphocytic Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

PGP GhiaVita-Salute San Raffaele UniversityJBJennifer R. BrownDana-Farber Cancer InstituteMSMazyar ShadmanUniversity of Washington Medical Center

Discussion

Loading...

Member takes

Implication

Comprehensive review examining zanubrutinib's efficacy and safety in chronic lymphocytic leukemia, indicating its potential as a preferred therapy.

Key Points

  • This review aims to evaluate the role of zanubrutinib in treating chronic lymphocytic leukemia (CLL) compared to other BTK inhibitors.
  • Reviewed pharmacologic properties of zanubrutinib versus ibrutinib and acalabrutinib.
  • Analyzed safety and efficacy data from head-to-head trials.
  • Focus on treatment guidelines recommending zanubrutinib and its role among BTK inhibitors.
  • Zanubrutinib showed superior overall response rates and prolonged progression-free survival compared to ibrutinib.
  • Improved safety outcomes with zanubrutinib included lower atrial fibrillation/flutter and infection rates.
  • Zanubrutinib is recommended over ibrutinib in treatment guidelines due to its superior safety profile, particularly reduced cardiotoxicity.

Cite This Study

Ghia et al. (2026) studied this question.

synapsesocial.com/papers/6a080a11a487c87a6a40bdeehttps://doi.org/10.1007/s40487-026-00443-w
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL2018 · 1,761 citations
  2. 2Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience2018 · 392 citations
  3. 3Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease2023 · 167 citations
  4. 4P632: COMPARISON OF TREATMENT-EMERGENT ADVERSE EVENTS OF ACALABRUTINIB AND ZANUBRUTINIB IN CLINICAL TRIALS IN B-CELL MALIGNANCIES: A SYSTEMATIC REVIEW AND META-ANALYSIS2023 · 7 citations
  5. 5Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase2019 · 364 citations